<?xml version="1.0" encoding="iso-8859-1"?>
	<!-- 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
		XML Comment inserted to enable XSL in Firefox 2.0 
	-->
	<?xml-stylesheet type="text/xsl" href="http://www.phgfoundation.org/public/templates/foundation_corp/xsl/newsletter.xsl"?>
	<rss version="2.0">
		<channel>
		<title>Articles from the PHG Foundation Newsletter</title>
		<link>http://www.phgfoundation.org/newsletter</link>
		<description>Articles from the PHG Foundation Newsletter</description>
		<copyright>PHG Foundation</copyright>
		<list_type>news</list_type>
		<customJS>http://www.phgfoundation.org/rss/newsletter.xml?format=js</customJS>
		
				<item>
			<title>Gene patenting and personalised medicine in the spotlight</title>
			<link>http://www.phgfoundation.org/news/month/04/2012/#story_11577</link>
			<pubDate>Wed, 04 Apr 2012 00:00:00 +0100</pubDate>
			<description><![CDATA[ The US Supreme Court has ordered a review of the most recent decision in favour of Myriad Genetics&amp;rsquo; BRCA1 and BRCA2 gene patents, in the light of a potentially contradictory ruling on a personalised medicine patent.  &amp;nbsp;  The latest decision in the long-running legal dispute, which began in ... ]]></description>
		</item>
				<item>
			<title>Opportunity to comment on US BRCA research plan</title>
			<link>http://www.phgfoundation.org/news/month/03/2012/#story_11444</link>
			<pubDate>Tue, 13 Mar 2012 00:00:00 +0000</pubDate>
			<description><![CDATA[ &amp;nbsp;The U.S. Preventative Services Task Force is asking the public to comment on its draft research plan Genetic Risk Assessment and&amp;nbsp;BRCA&amp;nbsp;Mutation Testing for Breast and Ovarian Cancer SusceptibilityProposed questions will consider the impact of risk assessment and BRCA mutation testing  ... ]]></description>
		</item>
				<item>
			<title>Fresh challenge for BRCA gene patent in Australia</title>
			<link>http://www.phgfoundation.org/news/month/02/2012/#story_11311</link>
			<pubDate>Fri, 24 Feb 2012 00:00:00 +0000</pubDate>
			<description><![CDATA[ The beleaguered Myriad Genetics, besides facing ongoing legal battles over BRCA gene patents in the US (see previous news), now faces challenge in the Australian courts.  &amp;nbsp;  The Federal Court is hearing a case against Myriad and their exclusive Australian licence holder for BRCA1 mutation testi ... ]]></description>
		</item>
				<item>
			<title>Calls for expanded BRCA1 genetic testing of women</title>
			<link>http://www.phgfoundation.org/news/month/02/2012/#story_11295</link>
			<pubDate>Thu, 23 Feb 2012 00:00:00 +0000</pubDate>
			<description><![CDATA[ New research has suggested that UK guidelines on genetic testing for breast cancer may need to be updated.  &amp;nbsp;  Cancer Research UK (CRUK) scientists analysed over 300 women with triple negative (TN) breast cancer and identified BRCA1 mutations in over 10% of them.  &amp;nbsp;  Current NICE guidance  ... ]]></description>
		</item>
				<item>
			<title>End of BRCA patent dispute may be in sight</title>
			<link>http://www.phgfoundation.org/news/month/02/2012/#story_11159</link>
			<pubDate>Thu, 02 Feb 2012 00:00:00 +0000</pubDate>
			<description><![CDATA[ Daniel Ravicher, executive director of PUBPAT, said: &amp;ldquo;Many scientists believe this case to be about critical questions of patient care and social policy. The decisions made in the lower court were highly fractious so this is precisely the kind of case the Supreme Court should hear&amp;rdquo;. ]]></description>
		</item>
				<item>
			<title>Ovarian cancer survival higher in BRCA mutation carriers</title>
			<link>http://www.phgfoundation.org/news/month/01/2012/#story_11108</link>
			<pubDate>Mon, 30 Jan 2012 00:00:00 +0000</pubDate>
			<description><![CDATA[ A new study has shown that women with inherited BRCA mutations have a better survival rate for ovarian cancer than women without such mutations.  &amp;nbsp;  Mutations in the BRCA1 and BRCA2 genes cause hereditary breast-ovarian cancer syndrome, where carriers have a substantially increased risk of deve ... ]]></description>
		</item>
				<item>
			<title>Women without BRCA mutations have normal cancer risk</title>
			<link>http://www.phgfoundation.org/news/month/11/2011/#story_10474</link>
			<pubDate>Fri, 11 Nov 2011 00:00:00 +0000</pubDate>
			<description><![CDATA[ Comment:&amp;nbsp;These apparently contradictory results highlight the difficulty of drawing general conclusions from isolated research projects, however well conducted. The new study involves around twice as many women as the earlier UK based one, which lends weight to their conclusions, but the most r ... ]]></description>
		</item>
				<item>
			<title>Earlier diagnosis of BRCA-cancers in younger generations</title>
			<link>http://www.phgfoundation.org/news/month/09/2011/#story_10025</link>
			<pubDate>Fri, 23 Sep 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[  ]]></description>
		</item>
				<item>
			<title>Insights into the function of BRCA1</title>
			<link>http://www.phgfoundation.org/news/month/09/2011/#story_9972</link>
			<pubDate>Sat, 17 Sep 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[  ]]></description>
		</item>
				<item>
			<title>Genetic testing company to favour trade secrets over patents</title>
			<link>http://www.phgfoundation.org/news/month/09/2011/#story_9830</link>
			<pubDate>Wed, 07 Sep 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[ Following the decision that Myriad Genetics should retain intellectual property rights over the BRCA1 and BRCA2 genes in the US (see previous news), there has been debate over the company&amp;rsquo;s future.  &amp;nbsp;  The BRCA tests accounted for around 88% of Myriad&amp;rsquo;s total revenue in the last yea ... ]]></description>
		</item>
				<item>
			<title>Myriad retains BRCA gene patents in latest legal ruling</title>
			<link>http://www.phgfoundation.org/news/month/08/2011/#story_9422</link>
			<pubDate>Fri, 05 Aug 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[ The US Federal Court of Appeals has ruled that the company Myriad Genetics is, after all, entitled to US patents held for the BRCA1&amp;nbsp;and&amp;nbsp;BRCA2&amp;nbsp;genes (see previous news), mutations in which are associated with hereditary breast-ovarian cancer syndrome.  &amp;nbsp;  This epic legal saga has  ... ]]></description>
		</item>
				<item>
			<title>Mapping of ovarian cancer genome</title>
			<link>http://www.phgfoundation.org/news/month/07/2011/#story_9035</link>
			<pubDate>Wed, 06 Jul 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[  ]]></description>
		</item>
				<item>
			<title>US gene patenting legal battle continues</title>
			<link>http://www.phgfoundation.org/news/month/04/2011/#story_8097</link>
			<pubDate>Sun, 10 Apr 2011 00:00:00 +0100</pubDate>
			<description><![CDATA[ The dispute is expected to reach the US Supreme Court eventually, with the outcome remaining far from clear; &amp;nbsp;the potential rift between the US Justice Department and Patent and Trademark Office continues. Certainly, the pressure for a change in gene patenting is rising; commentator Dan Vorhaus ... ]]></description>
		</item>
				<item>
			<title>Legal status of US gene patents in turmoil</title>
			<link>http://www.phgfoundation.org/news/month/11/2010/#story_6278</link>
			<pubDate>Fri, 05 Nov 2010 00:00:00 +0000</pubDate>
			<description><![CDATA[ Critics fear that restricting the scope of gene patents will have a detrimental effect on biomedical development by limiting potential financial returns on investment in research. Others contend this is unlikely because the manipulation of genes (for example, to create novel gene therapies or biosyn ... ]]></description>
		</item>
				<item>
			<title>Preventing cancer among BRCA mutation carriers by surgery</title>
			<link>http://www.phgfoundation.org/news/month/09/2010/#story_5689</link>
			<pubDate>Tue, 21 Sep 2010 00:00:00 +0100</pubDate>
			<description><![CDATA[ People with mutations in the BRCA1 or BRCA2 genes are at greatly increased risk of developing breast and ovarian cancers compared with the general population. Mutation carriers may receive increased levels of screening to detect tumours (more effective for breast than ovarian cancers), or they may o ... ]]></description>
		</item>
				<item>
			<title>Evidence for prostate cancer screening in high risk men</title>
			<link>http://www.phgfoundation.org/news/month/09/2010/#story_5678</link>
			<pubDate>Thu, 16 Sep 2010 00:00:00 +0100</pubDate>
			<description><![CDATA[ Prostate cancer is the most common cancer diagnosed in the UK, with three-quarters of the cases occurring in men over 65 (according to the CRUK), and there is increasing demand for screening in older men. The huge increase in cases of prostate cancer (despite a stable mortality rate) over the last 2 ... ]]></description>
		</item>
				<item>
			<title>Risk of breast cancer in male BRCA2 carriers</title>
			<link>http://www.phgfoundation.org/news/month/07/2010/#story_5571</link>
			<pubDate>Wed, 07 Jul 2010 00:00:00 +0100</pubDate>
			<description><![CDATA[ Mutations in the BRCA1 and BRCA2 genes cause hereditary breast-ovarian cancer syndrome, with a greatly increased risk of certain cancers (particularly breast cancer) in affected individuals. What is less commonly understood is that men who inherit mutations in these genes may also develop breast can ... ]]></description>
		</item>
				<item>
			<title>US genetic discrimination complaint</title>
			<link>http://www.phgfoundation.org/news/month/05/2010/#story_5414</link>
			<pubDate>Fri, 07 May 2010 00:00:00 +0100</pubDate>
			<description><![CDATA[ A woman has filed a complaint with the US Equal Opportunity Commission and Connecticut Commission on Human Rights and Opportunities against her former employers, claiming genetic discrimination after losing her job following genetic testing. She was identified as a carrier of a mutation in the BRCA2 ... ]]></description>
		</item>
				<item>
			<title>Latest twist in gene patent saga as BRCA patent revoked</title>
			<link>http://www.phgfoundation.org/news/month/03/2010/#story_5324</link>
			<pubDate>Tue, 30 Mar 2010 00:00:00 +0100</pubDate>
			<description><![CDATA[ In the latest legal reversal, a US judge has ruled that two patents held by Myriad Genetics for the diagnosis of mutations in the BRCA1 and BRCA2 genes associated with inherited predisposition to breast-ovarian cancer syndrome are invalid.   Legal action was taken against the company along with join ... ]]></description>
		</item>
				<item>
			<title>New cancer drug targets BRCA mutations</title>
			<link>http://www.phgfoundation.org/news/month/06/2009/#story_4690</link>
			<pubDate>Fri, 26 Jun 2009 00:00:00 +0100</pubDate>
			<description><![CDATA[ Cancer arises when a series of mutations accumulate that act together to block normal DNA repair (correction of spontaneous mutations) and deregulate normal control over cellular proliferation. A paper in the New England Journal of Medicine reports the results of a phase I clinical trial for a novel ... ]]></description>
		</item>
			</channel>
</rss>
